
PTHS Stock Forecast & Price Target
PTHS Analyst Ratings
Bulls say
Pelthos Therapeutics Inc. has demonstrated robust growth in prescription volumes, with a notable 41% sequential increase in October 2025, which surpasses the total prescriptions written in the prior third quarter. The company plans to expand its sales force from 50 to 64 territory managers by early 2026, which is expected to enhance its market coverage and bolster its revenue from products like Xepi within a large untapped market. With a positive trajectory in prescriber adoption and treatment rates projected to rise, Pelthos is well-positioned to capitalize on its innovative product offerings and operational efficiencies, indicating strong potential for future financial performance.
Bears say
Pelthos Therapeutics Inc faces significant challenges that could negatively impact its financial outlook and stock performance. If the company fails to secure adequate reimbursement levels and formulary placements, projected sales and margins may suffer due to slower-than-expected market adoption among healthcare professionals and payers. Additionally, the potential for its clinical-stage products to deliver statistically insignificant results in late-stage trials, along with the risk of regulatory approval failures and increased competition, further exacerbates concerns about revenue growth and overall company value.
This aggregate rating is based on analysts' research of Pelthos Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
PTHS Analyst Forecast & Price Prediction
Start investing in PTHS
Order type
Buy in
Order amount
Est. shares
0 shares